Valuation -- 6/10
ILMN trades at 24.9x FY2026E non-GAAP EPS (~$5.12 midpoint), in line with Agilent (25.6x)
and Danaher (24.5x) but at a premium to Thermo Fisher (20x). The stock has rallied ~62% off
52-week lows and sits above the consensus analyst price target of ~$124-$132. Consensus rating
is Hold. The valuation embeds a successful turnaround and continued clinical momentum -- limited
margin of safety if the trajectory stalls. The post-GRAIL spinoff turnaround under new CEO Jacob
Thaysen is real, with FY2025 beating and raising through the year, but the good news is largely
in the price. Risk/reward is balanced at current levels, not asymmetrically attractive.
Weight: 15%
Forward P/E (FY26E)
24.9x
vs TMO 20x, DHR 24.5x, A 25.6x
Trailing P/E
23.4x
TTM non-GAAP EPS $4.85
EV/Revenue
~4.5x
vs TMO 4.4x, PACB 2.3x
Market Cap
$19.5B
Price $127.31, near 52-wk high
Valuation context
| Metric | ILMN | Context |
|---|---|---|
| Price | $127.31 | Up ~62% from 52-wk low; near 52-wk high |
| Forward P/E (FY26E) | 24.9x | Non-GAAP EPS $5.05-$5.20 (midpoint ~$5.12) |
| Trailing P/E | 23.4x | FY2025 non-GAAP EPS $4.85 |
| EV/Revenue | ~4.5x | vs TMO 4.4x; PACB 2.3x (unprofitable) |
| Revenue (FY2025) | $4.34B | FY2026 guide: $4.50B-$4.60B (+4-6%) |
| Non-GAAP Op Margin | 22.75-23.0% | FY2026 guide: 23.3-23.5%; target 26% by 2027 |
| Free Cash Flow (FY2025) | ~$932M | Strong improvement; ~$1B annual run-rate |
| Buyback Authorization | $643M remaining | ~$740M returned in FY2025 |
| Consensus Rating | Hold | Consensus PT ~$124-$132; stock above midpoint |
Peer multiples
| Company | Fwd P/E | EV/Rev | Status |
|---|---|---|---|
| ILMN (Illumina) | 24.9x | ~4.5x | Profitable, ~$1B FCF |
| TMO (Thermo Fisher) | 20.0x | ~4.4x | Diversified life sciences; lower-growth, lower-risk |
| DHR (Danaher) | 24.5x | -- | Diversified diagnostics/life sciences |
| A (Agilent) | 25.6x | -- | Analytical instruments; similar multiple |
| PACB (PacBio) | NM | ~2.3x | Unprofitable; $0.4B mkt cap |
ILMN trades in line with life sciences peers on forward P/E. The premium to TMO reflects
higher growth expectations from clinical sequencing. The discount to historical 30-40x range
reflects post-GRAIL trust deficit and competitive concerns.
Guidance evolution (FY2025 to FY2026)
| Metric | FY25 Initial (Q1) | FY25 Final (Q4) | FY26 Guide | Trend |
|---|---|---|---|---|
| Revenue | $4.18B-$4.26B | $4.27B-$4.31B | $4.50B-$4.60B | Beat/raised all year |
| Non-GAAP Op Margin | 21.5%-22.0% | 22.75%-23.0% | 23.3%-23.5% | +130bp guided YoY |
| Non-GAAP EPS | $4.20-$4.30 | $4.65-$4.75 | $5.05-$5.20 | +8-10% YoY at midpoint |
Management beat and raised through all of FY2025, building credibility. FY2026 guide methodology is
described as conservative. Data sourced from Daloopa.
Quarterly earnings and cash flow trajectory
| Metric | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 |
|---|---|---|---|---|---|---|---|---|
| Non-GAAP EPS | $0.98 | $1.09 | $1.14 | $0.95 | $0.97 | $1.19 | $1.34 | $1.35 |
| FCF ($M) | $41 | $48 | $284 | $322 | $208 | $204 | $253 | $267 |
| Gross Margin (Core) | 65.7% | 68.0% | 68.9% | -- | 65.6% | 65.6% | 67.6% | -- |
EPS trajectory inflecting higher through FY2025. FCF stepped up materially in H2 2024 and sustained
through 2025. Gross margins impacted ~200bp by tariffs. Data sourced from Daloopa.
Catalysts
| # | Catalyst | Timing | Probability | Impact |
|---|---|---|---|---|
| 1 | Clinical consumable acceleration | Ongoing 2026 | High | High |
| Q4 2025 clinical consumables grew 20% ex-China. Guided double-digit to mid-teens clinical growth in 2026. Driven by MRD, whole genome, expanded reimbursement. | ||||
| 2 | Operating margin expansion to 26% target | 2026-2027 | Medium-High | Medium |
| +130bp guided expansion in FY2026 (ex-Somalogic). On track toward 26% by 2027. Q4 2025 exit rate was 23.7%, trending in the right direction. | ||||
| 3 | NIH funding stabilization | H2 2026 | Medium | Medium-High |
| Recent NIH budget announcements provide better line of sight. If grant flow resumes, research consumables (currently declining mid-to-high single digits) could stabilize, providing upside to guidance. | ||||
| 4 | Population genomics programs ramp | 2026-2028 | Medium | Medium |
| UK Biobank (490K genomes analyzed), All of Us, and 20+ national biobanks worldwide. DRAGEN platform is the standard. New proteomics pilot with UK Biobank (50K samples). | ||||
| 5 | Multiomics product launches | 2026 | Medium | Medium |
| Spatial transcriptomics and Constellation MAP Read expected in 2026. Somalogic adds proteomics. Management expects 1-2% incremental growth from multiomics by 2027. | ||||
| 6 | BioInsight / pharma data monetization | 2026-2028 | Medium-Low | Medium |
| Billion Cell Atlas launched with AstraZeneca, Merck, Eli Lilly collaborations. Subscription-based data/AI model for pharma. Still early stage. | ||||
| 7 | China resolution / UAL removal | 2026+ | Low-Medium | Medium |
| China is less than 5% of revenue. If export restrictions ease and UAL is resolved, upside to $210-$220M China guidance. Management describes good conversations. | ||||
| 8 | NovaSeq 6K-to-X transition completion | End of 2026 | High | Low-Medium |
| 6K transition substantially complete by end of 2026 per CFO. Removes pricing headwind overhang from conversion dynamics. | ||||
| 9 | Share buyback support | Ongoing | High | Low |
| $643M remaining authorization. ~$740M returned in FY2025. ~$1B annual FCF supports continued repurchases. | ||||
Key risks
| # | Risk | Severity | Probability | Detail |
|---|---|---|---|---|
| 1 | NIH budget cuts (40% reduction proposed) | HIGH | Medium-High | Academic/government customers (~30-40% of research revenue) could significantly curtail spending. Guidance already assumes mid-to-high single-digit decline in research consumables, but deeper cuts could exceed assumptions. |
| 2 | Intensifying competition (Element, Ultima, Roche) | MEDIUM-HIGH | Medium-High | Element (AVITI), Ultima (UG200 at sub-$1/Gb), and Roche (SBX launching 2026) all targeting share. Roche entry in clinical sequencing is the most significant new threat. |
| 3 | China export restrictions / UAL listing | MEDIUM | Medium | ~7% of revenue at risk per HSBC. Instruments cannot be directly exported; OEM workaround is partial. Management does not expect current China momentum to persist. |
| 4 | Tariff headwinds on gross margins | MEDIUM | Medium-High | Tariffs impacted gross margins by ~200bp in 2025. Further escalation could stall gross margin recovery. Q4 2025 GM of 67% was down 40bp YoY. |
| 5 | Valuation premium / stock above consensus | MEDIUM | High | Stock at $127 trades above the $124-$132 analyst consensus range. Up ~62% from 52-week lows. Limited upside if execution merely meets expectations. |
| 6 | Research market structural decline | MEDIUM | Medium | Research and applied consumables declining for multiple quarters. Secular shift toward clinical may be permanent; research may not recover to prior growth levels. |
| 7 | Somalogic integration / dilution | LOW-MEDIUM | Medium-Low | $350M upfront acquisition. Expected $0.18 dilutive to EPS and 100bp drag on margins in 2026. Integration execution risk exists. |
| 8 | Clinical customer concentration | MEDIUM | Low-Medium | Clinical is primary growth driver with over 60% of X placements. Heavy reliance on concentrated large clinical customers creates platform-switching risk. |
| 9 | FX volatility | LOW | Medium | International revenue exposure. FX expected to add ~1pt to reported growth in 2026 but could reverse. |
Scenario analysis
| Scenario | Prob. | Price Range | Implied Return | Key Assumptions |
|---|---|---|---|---|
| Bull | 25% | $150-$170 | +18% to +34% | NIH stabilizes, clinical 15%+, China resolved, research flat, margins 25%+, multiomics traction |
| Base | 55% | $115-$140 | -10% to +10% | Guidance achieved ($5.05-$5.20 EPS), clinical mid-teens, research down mid-single, China ~$215M |
| Bear | 20% | $80-$100 | -21% to -37% | NIH cuts deeper, Roche/Element take share, China deteriorates, tariff escalation, clinical decelerates |
Base case is most probable at 55%. Current price of $127 sits in the upper half of the base range,
suggesting limited margin of safety. Probability-weighted expected value is roughly in line with
the current price -- neither cheap nor expensive, but not asymmetrically attractive.
Bull and bear scenarios
Bull Case ($150-$170, +18-34% upside)
- NIH funding stabilizes, research consumables recover to flat
- Clinical sequencing grows 15%+ driven by MRD and whole genome
- China resolved -- UAL removed, instrument imports resume
- Operating margins reach 25%+ in 2026, ahead of 26% 2027 target
- Population genomics programs (UK Biobank, All of Us) drive incremental volume
- Multiomics (spatial, proteomics) gains traction ahead of schedule
Bear Case ($80-$100, -21-37% downside)
- NIH cuts deeper than expected, academic spending collapses
- Roche SBX and Element AVITI take meaningful clinical share
- China deteriorates further, UAL not resolved
- Tariff escalation stalls gross margin recovery
- Clinical growth decelerates to single digits as competitive pressure mounts
- Somalogic integration stumbles, dilution exceeds expectations
Key monitoring items -- next earnings May 7, 2026
| # | Item | What to Watch |
|---|---|---|
| 1 | Q1 clinical consumable growth rate | Does the 20% ex-China Q4 run-rate sustain? Guided 1-3% RoW organic for Q1. |
| 2 | Research consumable trajectory | Any signs of NIH grant flow resumption? |
| 3 | China instrument imports | Any movement on UAL status or regulatory approval for direct exports? |
| 4 | Competitive commentary | Any customer defections to Element, Ultima, or Roche? AGBT conference takeaways. |
| 5 | Gross margin ex-tariffs | Is underlying margin expanding as NovaSeq X transition completes? |
| 6 | Somalogic integration | Revenue contribution and dilution tracking vs $0.18 EPS drag estimate. |
Score rationale
Score of 6/10 reflects a balanced but watchful risk/reward profile where the turnaround is real but largely priced in.
Why not higher (7-8): The stock has rallied ~62% off 52-week lows and trades above the consensus analyst price target of ~$124-$132. At 24.9x forward P/E, ILMN is priced for continued execution with little margin of safety. Analyst consensus is Hold. The biggest risks -- NIH funding cuts (40% proposed reduction), intensifying competition from Element, Ultima, and Roche, and China export restrictions -- are all non-trivial and could individually derail the trajectory. Research consumables have been declining for multiple quarters with no clear bottom. Tariffs have already impacted gross margins by ~200bp. Somalogic adds $0.18 EPS dilution in 2026.
Why not lower (4-5): The turnaround under CEO Jacob Thaysen is credible -- management beat and raised through all of FY2025 with conservative guidance methodology. Clinical consumables grew 20% ex-China in Q4 2025, a genuinely strong result. FCF inflected to ~$1B annually, supporting $740M in buybacks. The balance sheet is clean (~1.6x leverage). Operating margins are expanding toward the 26% target. The consumables razor/blade model provides recurring revenue visibility. Population genomics and multiomics are credible medium-term growth vectors.
Net assessment: ILMN is a quality franchise in turnaround mode, but the stock price has already recognized the improvement. The risk/reward is balanced at current levels -- not asymmetrically attractive for new positions. HOLD / Watchlist. Next earnings May 7, 2026. Score: 6/10.
Data sourced from Daloopa, company earnings transcripts, and public filings. Analysis as of April 2026.